SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on January 16, 2003; DOI 10.1182/blood-2002-09-2778. This Article Full Text (PDF) All Versions of this Article: 2002-09-2778v1 101/10/3875    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Elstrom, R. Articles by Schuster, S. J Search for Related Content PubMed PubMed Citation Articles by Elstrom, R. Articles by Schuster, S. J Social Bookmarking                   What's this? Submitted September 11, 2002 Accepted January 11, 2003 Utility of FDG-PET scanning in lymphoma by WHO classification Rebecca Elstrom*, Liang Guan, Khozaim Nakhoda, Gary Baker, Jo-Anne Vergilio, Hongming Zhuang, Stephanie Pitsilos, Adam Bagg, Lisa Downs, Amit Mehrotra, Scott Kim, Abass Alavi, and Stephen J Schuster Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA Department of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, USA Department of Laboratory Medicine and Pathology, University of Pennsylvania, Philadelphia, PA, USA * Corresponding author; email: relstrom{at}mail.med.upenn.edu. We retrospectively evaluated FDG-PET scans in 172 patients with lymphoma and correlated results with pathologic diagnosis using the WHO classification system. In total, FDG-PET detected disease in at least one site in 161 patients (94%) and failed to detect disease in 11 patients (6%). The most frequent lymphoma diagnoses were diffuse large B-cell lymphoma (LBCL; n=51), Hodgkin lymphoma (HL; n=47), follicular lymphoma (FL; n=42), marginal zone lymphoma (MZL; n=12), mantle cell lymphoma (MCL; n=7) and peripheral T-cell lymphoma (PTCL; n=5). FDG-PET detected disease in 100% of patients with LBCL and MCL, and 98% of patients with HL and FL. In contrast, FDG-PET detected disease in only 67% of MZL and 40% of PTCL. Comparison with bone marrow biopsies showed that FDG-PET was not reliable for detection of bone marrow involvement in any lymphoma subtype. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Delbeke, S. Stroobants, E. de Kerviler, C. Gisselbrecht, M. Meignan, and P. S. Conti Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma Oncologist, October 1, 2009; 14(suppl_2): 30 - 40. [Abstract] [Full Text] [PDF] G. Matharu, D. Wilson, V. Sumathi, and T. Butt Spinal cord compression: to biopsy, or not to biopsy? BMJ Case Reports, August 20, 2009; 2009(aug20_2): bcr0320091657 - bcr0320091657. [Abstract] [Full Text] M. Hutchings and S. F. Barrington PET/CT for Therapy Response Assessment in Lymphoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S. [Abstract] [Full Text] [PDF] A. Psyrri, S. Papageorgiou, and T. Economopoulos Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management Ann. Onc., December 1, 2008; 19(12): 1992 - 1999. [Abstract] [Full Text] [PDF] C. Bodet-Milin, F. Kraeber-Bodere, P. Moreau, L. Campion, B. Dupas, and S. Le Gouill Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma Haematologica, March 1, 2008; 93(3): 471 - 472. [Abstract] [Full Text] [PDF] T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein Imaging in staging of malignant lymphoma: a systematic review Blood, January 15, 2008; 111(2): 504 - 516. [Abstract] [Full Text] [PDF] S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 43 - 48. [Abstract] [Full Text] [PDF] C. Ansquer, T. Hervouet, A. Devillers, S. de Guibert, T. Gastinne, S. Le Gouill, E. Garin, A. Moreau, F. Kraeber-Bodere, and T. Lamy 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease Haematologica, January 1, 2008; 93(1): 128 - 131. [Abstract] [Full Text] [PDF] A. S. Perkins and J. W. Friedberg Burkitt Lymphoma in Adults Hematology, January 1, 2008; 2008(1): 341 - 348. [Abstract] [Full Text] [PDF] P. Seam, M. E. Juweid, and B. D. Cheson The role of FDG-PET scans in patients with lymphoma Blood, November 15, 2007; 110(10): 3507 - 3516. [Abstract] [Full Text] [PDF] S. Kako, K. Izutsu, Y. Ota, Y. Minatani, M. Sugaya, T. Momose, K. Ohtomo, Y. Kanda, S. Chiba, T. Motokura, et al. FDG-PET in T-cell and NK-cell neoplasms Ann. Onc., October 1, 2007; 18(10): 1685 - 1690. [Abstract] [Full Text] [PDF] M. E. Juweid, S. Stroobants, O. S. Hoekstra, F. M. Mottaghy, M. Dietlein, A. Guermazi, G. A. Wiseman, L. Kostakoglu, K. Scheidhauer, A. Buck, et al. Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 571 - 578. [Abstract] [Full Text] [PDF] B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al. Revised Response Criteria for Malignant Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 579 - 586. [Abstract] [Full Text] [PDF] A. Reiter Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma Hematology, January 1, 2007; 2007(1): 285 - 296. [Abstract] [Full Text] [PDF] P. Venugopal and S. A. Gregory Lymphoproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 265 - 297. [Full Text] [PDF] Y. L. Kasamon, R. J. Jones, and R. L. Wahl Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma J. Nucl. Med., January 1, 2007; 48(1_suppl): 19S - 27S. [Abstract] [Full Text] [PDF] Y. S. Jhanwar and D. J. Straus The Role of PET in Lymphoma J. Nucl. Med., August 1, 2006; 47(8): 1326 - 1334. [Abstract] [Full Text] [PDF] E. Y. Tsai, A. Taur, L. Espinosa, A. Quon, D. Johnson, S. Dick, S. Chow, R. Advani, R. Warnke, S. Kohler, et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol, May 1, 2006; 142(5): 577 - 584. [Abstract] [Full Text] [PDF] S. Wohrer, U. Jaeger, K. Kletter, A. Becherer, A. Hauswirth, K. Turetschek, M. Raderer, and M. Hoffmann 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading Ann. Onc., May 1, 2006; 17(5): 780 - 784. [Abstract] [Full Text] [PDF] M. E. Juweid and B. D. Cheson Positron-Emission Tomography and Assessment of Cancer Therapy N. Engl. J. Med., February 2, 2006; 354(5): 496 - 507. [Full Text] [PDF] M. E. Juweid Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 259 - 265. [Abstract] [Full Text] [PDF] D. Hollister Jr, M. S. Lee, R. N. Eisen, C. Fey, and C. S. Portlock Variable Problems in Lymphomas: CASE 2. Sarcoidosis Mimicking Progressive Lymphoma J. Clin. Oncol., November 1, 2005; 23(31): 8113 - 8116. [Full Text] [PDF] H. Schoder, A. Noy, M. Gonen, L. Weng, D. Green, Y. E. Erdi, S. M. Larson, and H. W.D. Yeung Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., July 20, 2005; 23(21): 4643 - 4651. [Abstract] [Full Text] [PDF] E. E. Pakos, A. D. Fotopoulos, and J. P.A. Ioannidis 18F-FDG PET for Evaluation of Bone Marrow Infiltration in Staging of Lymphoma: A Meta-Analysis J. Nucl. Med., June 1, 2005; 46(6): 958 - 963. [Abstract] [Full Text] [PDF] G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF] K. P. Beal, H. W. Yeung, and J. Yahalom FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases Ann. Onc., March 1, 2005; 16(3): 473 - 480. [Abstract] [Full Text] [PDF] T. Kazama, S. C. Faria, V. Varavithya, S. Phongkitkarun, H. Ito, and H. A. Macapinlac FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls RadioGraphics, January 1, 2005; 25(1): 191 - 207. [Abstract] [Full Text] [PDF] J. E. Thompson and C. B. Thompson Putting the Rap on Akt J. Clin. Oncol., October 15, 2004; 22(20): 4217 - 4226. [Abstract] [Full Text] [PDF] R. L. Elstrom, D. E. Bauer, M. Buzzai, R. Karnauskas, M. H. Harris, D. R. Plas, H. Zhuang, R. M. Cinalli, A. Alavi, C. M. Rudin, et al. Akt Stimulates Aerobic Glycolysis in Cancer Cells Cancer Res., June 1, 2004; 64(11): 3892 - 3899. [Abstract] [Full Text] [PDF] R. M. Meyer, R. F. Ambinder, and S. Stroobants Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice Hematology, January 1, 2004; 2004(1): 184 - 202. [Abstract] [Full Text] [PDF] J. W. Friedberg and V. Chengazi PET Scans in the Staging of Lymphoma: Current Status Oncologist, October 1, 2003; 8(5): 438 - 447. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020